手机购彩

Hengrui has built a high-standard production base and formed a production system with clear division of labor and unified coordination.

① Lianyungang API production base: The total investment is over USD 60 million, covering an area of 275 acres. It is designed and constructed in accordance with US FDA standards. It is mainly engaged in the research and development and production of pharmaceutical raw materials.

② Lianyungang international production base of pharmaceutical preparations: a total investment of 350 million yuan, covering an area of 100 acres, with advanced production equipment, a modern preparation workshop, and a production base that complies with US FDA standards.

③ Lianyungang Bio-pharmaceutical Production Base: With a total investment of 1.5 billion yuan and an area of about 235 acres, an advanced bio-pharmaceutical research and development center will be built to form a pharmaceutical bio-industrial park with independent innovation capabilities and international competitiveness.

④ Lianyungang New Pharmaceutical Industrial Park: It covers an area of 326 acres with a total investment of about 2 billion yuan. Its design and construction are in accordance with the US FDA standards. It has been established as an industrial base for innovative drugs and high-end export preparations.

⑤Chengdu pharmaceutical production base: a total investment of 500 million yuan, while building a production base of raw materials and preparations, of which the preparation base covers an area of 155 acres, and the raw material base covers an area of 200 acres.

⑥ Suzhou Biomedicine R & D and Production Base: A total investment of 1.5 billion yuan, covering an area of 165 acres, mainly producing antibodies and other biological drugs. A high-level biomedical R & D and production base will be built, and advanced purification, ultrafiltration, and analysis equipment will be introduced to create Comply with US FDA and EU EMA quality certification production system.

⑦Shanghai preparation production base: a total investment of 200 million yuan, covering an area of 90 acres, and construction of lyophilized powder injections, nasal sprays, solutions and other production workshops that meet the US FDA standards.